264 related articles for article (PubMed ID: 37235767)
21. [Dermatology. New uses for JAK inhibitors in dermatology: a panacea, but at what price?].
Russo G; Laffitte E; Cortes B
Rev Med Suisse; 2024 Jan; 20(859):241-246. PubMed ID: 38299954
[TBL] [Abstract][Full Text] [Related]
22. JAK inhibitors for the treatment of vitiligo.
Inoue S; Suzuki T; Sano S; Katayama I
J Dermatol Sci; 2024 Mar; 113(3):86-92. PubMed ID: 38326166
[TBL] [Abstract][Full Text] [Related]
23. Janus Kinase Inhibitors in the Treatment of Vitiligo: A Review.
Qi F; Liu F; Gao L
Front Immunol; 2021; 12():790125. PubMed ID: 34868078
[TBL] [Abstract][Full Text] [Related]
24. Off-label Studies on the Use of Ruxolitinib in Dermatology.
Tegtmeyer K; Ravi M; Zhao J; Maloney NJ; Lio PA
Dermatitis; 2021 May-Jun 01; 32(3):164-172. PubMed ID: 33443378
[TBL] [Abstract][Full Text] [Related]
25. JAK inhibitors in dermatology: The promise of a new drug class.
Damsky W; King BA
J Am Acad Dermatol; 2017 Apr; 76(4):736-744. PubMed ID: 28139263
[TBL] [Abstract][Full Text] [Related]
26. Differential properties of Janus kinase inhibitors in the treatment of immune-mediated inflammatory diseases.
Taylor PC; Choy E; Baraliakos X; Szekanecz Z; Xavier RM; Isaacs JD; Strengholt S; Parmentier JM; Lippe R; Tanaka Y
Rheumatology (Oxford); 2024 Feb; 63(2):298-308. PubMed ID: 37624925
[TBL] [Abstract][Full Text] [Related]
27. Evaluating topical JAK inhibitors as a treatment option for atopic dermatitis.
Fardos MI; Singh R; Perche PO; Kelly KA; Feldman SR
Expert Rev Clin Immunol; 2022 Mar; 18(3):221-231. PubMed ID: 34637367
[TBL] [Abstract][Full Text] [Related]
28. Safety of Janus kinase (JAK) inhibitors in the short-term treatment of atopic dermatitis.
Wood H; Chandler A; Nezamololama N; Papp K; Gooderham MJ
Int J Dermatol; 2022 Jun; 61(6):746-754. PubMed ID: 34423443
[TBL] [Abstract][Full Text] [Related]
29. Deucravacitinib is an allosteric TYK2 protein kinase inhibitor FDA-approved for the treatment of psoriasis.
Roskoski R
Pharmacol Res; 2023 Mar; 189():106642. PubMed ID: 36754102
[TBL] [Abstract][Full Text] [Related]
30. Role of janus kinase inhibitors in the treatment of alopecia areata.
Triyangkulsri K; Suchonwanit P
Drug Des Devel Ther; 2018; 12():2323-2335. PubMed ID: 30100707
[TBL] [Abstract][Full Text] [Related]
31. Tyrosine kinase 2 and Janus kinase‒signal transducer and activator of transcription signaling and inhibition in plaque psoriasis.
Krueger JG; McInnes IB; Blauvelt A
J Am Acad Dermatol; 2022 Jan; 86(1):148-157. PubMed ID: 34224773
[TBL] [Abstract][Full Text] [Related]
32. Innovation in the treatment of atopic dermatitis: Emerging topical and oral Janus kinase inhibitors.
Nakashima C; Yanagihara S; Otsuka A
Allergol Int; 2022 Jan; 71(1):40-46. PubMed ID: 34815171
[TBL] [Abstract][Full Text] [Related]
33. Inhibition of the JAK-STAT Pathway in the Treatment of Psoriasis: A Review of the Literature.
Furtunescu AR; Georgescu SR; Tampa M; Matei C
Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38731900
[TBL] [Abstract][Full Text] [Related]
34. Novel Clinical Applications of Topical Ruxolitinib: A Case Series.
Zundell MP; Al-Dehneem R; Song T; Yousif J; Gottlieb AB
J Drugs Dermatol; 2024 Mar; 23(3):188-190. PubMed ID: 38443119
[TBL] [Abstract][Full Text] [Related]
35. Tofacitinib, an Oral Janus Kinase Inhibitor: Perspectives in Dermatology.
Kostovic K; Gulin SJ; Mokos ZB; Ceovic R
Curr Med Chem; 2017 May; 24(11):1158-1167. PubMed ID: 28088907
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of ruxolitinib cream 1.5% as an at-home therapy for repigmentation in non-segmental vitiligo.
Agner ML; Parraga SP; Arkhipenko ZM; Pichardo RO; McMichael AJ; Feldman SR
Expert Rev Clin Immunol; 2024 Jul; 20(7):695-702. PubMed ID: 38879876
[TBL] [Abstract][Full Text] [Related]
37. Pharmacodynamics of Janus kinase inhibitors for the treatment of atopic dermatitis.
Calabrese L; Chiricozzi A; De Simone C; Fossati B; D'Amore A; Peris K
Expert Opin Drug Metab Toxicol; 2022 May; 18(5):347-355. PubMed ID: 35796377
[TBL] [Abstract][Full Text] [Related]
38. Discovery and Characterization of the Topical Soft JAK Inhibitor CEE321 for Atopic Dermatitis.
Thoma G; Duthaler RO; Waelchli R; Hauchard A; Bruno S; Strittmatter-Keller U; Orjuela Leon A; Viebrock S; Aichholz R; Beltz K; Grove K; Hoque S; Rudewicz PJ; Zerwes HG
J Med Chem; 2023 Feb; 66(3):2161-2168. PubMed ID: 36657024
[TBL] [Abstract][Full Text] [Related]
39. Application of JAK inhibitors in paradoxical reaction through immune-related dermatoses.
Zhang Y; Jiang G
Front Immunol; 2024; 15():1341632. PubMed ID: 38444845
[TBL] [Abstract][Full Text] [Related]
40. JAK/STAT inhibitors for the treatment of atopic dermatitis.
Rodrigues MA; Torres T
J Dermatolog Treat; 2020 Feb; 31(1):33-40. PubMed ID: 30703333
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
